Patents by Inventor Robert Scott Pearsall

Robert Scott Pearsall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
    Patent number: 10829533
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: November 10, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • TGFBETA AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
    Publication number: 20200306340
    Abstract: Disclosed herein are TGF? and ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients.
    Type: Application
    Filed: January 31, 2018
    Publication date: October 1, 2020
    Inventors: Robert Scott Pearsall, Ravindra Kumar
  • ALK4:ActRIIB heteromultimers and uses thereof
    Patent number: 10738098
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 11, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20200208124
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: July 2, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20200199546
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20200199547
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20200199548
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS
    Publication number: 20200199186
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Applicant: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
    Patent number: 10689427
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: June 23, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS
    Publication number: 20200181217
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS
    Publication number: 20200181218
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20200165583
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: June 27, 2019
    Publication date: May 28, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ALK7 ANTAGONISTS AND USES THEREOF
    Publication number: 20200048355
    Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 13, 2020
    Inventors: John Knopf, Ravindra Kumar, Asya Grinberg, Robert Scott Pearsall, Dianne S. Sako, Roselyne Castonguay, Gang Li, Yossi Dagon
  • ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20190375820
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 12, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
  • COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS
    Publication number: 20190263876
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: October 11, 2018
    Publication date: August 29, 2019
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Methods of identifying ActRIIB variants
    Patent number: 10377996
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 13, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
    Publication number: 20190225669
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20190218272
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 18, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20190100570
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 4, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK7:ActRIIB heteromultimers and uses thereof
    Patent number: 10227392
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 12, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf